Grifols | GRFS - Cash And Equivalent


Grifols reported EUR979.78M in Cash and Equivalent for its fiscal quarter ending in December of 2024.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Arca Biopharma USD 91.25M 25.86M Sep/2025
aTyr Pharma USD 6.15M 11.07M Sep/2025
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 5K 819K Sep/2025
Capricor Therapeutics USD 287.85M 268.34M Dec/2025
Cara Therapeutics USD 20.65M 13.57M Jun/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Immunic USD 35.13M 20.18M Sep/2025
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
TherapeuticsMD 523K 89K Jun/2024